This product is for wholesale purchases only.
Bulk orders must meet the 20 unit minimum per item/Per mg. Please contact us directly for bulk pricing. EMAIL
**You will be required to provide proof of a resale certificate within the Health & Wellness industry in order to recieve pricing.
This item has been tested and certified by a USA based 3rd party lab. These documents are available upon request.
- Retatrutide is triple agonist GLP weight managment supplement via subqutaneous injection.
- Custom branded lables and individual vial boxes are available to showcase your brand. Otherwise these will come blank or with our basic branding and labling, per customer request (Sample image has been provided).
- For branding & pricing please contact us directly to discuss your artwork and requirements.
Production and Delivery:
Blank Vials, no branding bulk pack (7-10 days)
Branded Vials bulk packaged (10-14 days)
Branded Vials and Vial Boxes (20-30 days)
Retatrutide 10mg | 15mg | 20mg | 30mg
Retatrutide is an investigational, once-weekly injectable medication being developed for the treatment of obesity and type 2 diabetes. It works by activating three key hormones involved in appetite and blood sugar regulation: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon. By targeting all three, retatrutide may promote significant weight loss and improved glycemic control.
Mechanism of Action
Retatrutide mimics the effects of GIP, GLP-1, and glucagon. This combined action helps slow gastric emptying, enhances feelings of fullness, and stabilizes blood sugar levels. These effects contribute to reduced calorie intake and better management of glucose levels.
Clinical Trials
Early studies suggest that retatrutide may lead to greater weight loss than currently approved GLP-1 receptor agonists, such as semaglutide (marketed as Ozempic and Wegovy). These findings highlight its potential as a powerful new option in the treatment of metabolic diseases.
Potential Benefits
Beyond weight reduction, retatrutide is also being evaluated for its ability to lower liver fat content in individuals with obesity, and to support better control of type 2 diabetes.
Development Status
Although clinical results are promising, retatrutide remains in the research and development phase and has not yet been approved by regulatory bodies such as the U.S. Food and Drug Administration (FDA).
Administration
If approved, retatrutide would be administered via a once-weekly subcutaneous injection, similar to other medications in its class.